- National Biotechnology Development Strategy (External website that opens in a new window)
- Guidelines to Develop Proposals in the area of Pharmacogenomics (External website that opens in a new window)
- Regulatory Reforms in Biotechnology (External website that opens in a new window)
- Ethical Policies in the Human Genome, Genetic R & S (External website that opens in a new window)
- Plant Biotechnology (External website that opens in a new window)
- Biotech Product & Process Development (External website that opens in a new window)
Concerted efforts have been made towards development of vaccines and diagnostics for the major infectious and non-infectious diseases specially in the areas of tuberculosis, avian influenza, Chikungunya, rotavirus, typhoid, malaria and HPV. New DBT-ICMR collaborative efforts has been initiated on HIV/AIDS and Microbicides research. About 20 projects have been implemented under this joint effort. Brain storming sessions were organized on future R&D efforts on avian influenza, Chikungunya and other infectious diseases. Emphasis was also laid on setting up virus research network projects. Typhoid vaccine development technology was transferred to an industry for further Current good manufacturing practices (cGMP) grade production, pre-clinical and clinical studies.
A rapid diagnostics test system for filariasis (Signal MF) developed by Anna University, Chennai has been commercially launched. More than 100 new projects have been recommended for support in various infectious and chronic diseases areas. Efforts have been initiated to study molecular evolution and for the development of cost effective and easily up scalable multivalent vaccine for avian influenza (H5N1). Leads obtained in various researches are being persuaded for product/process developments. Studies on development of a lentivirus based high efficiency gene transfer vector has culminated towards development of indigenous gene transfer vector with novel features of versatile multiple cloning site with expended cloning capabilities. An agreement has been signed between DBT and IAVI to pursue the biomedical research programme towards vaccine development of HIV/AIDS, and collaborative programme Neutralizing Antibody Consortium is going to be initiated soon. Follow up actions have been initiated on the leads available towards development of newer diagnostic systems, better therapeutics, RNAI and newer vaccines.
Source: National Portal Content Management Team, Reviewed on: 09-02-2011